⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99597 | 1.00 | — | — | |
| SCHEMBL99596 | 1.00 | — | — | |
| SCHEMBL521914 | 0.97 | ALDH1A1 (0.35) | — | |
| SCHEMBL521913 | 0.97 | ALDH1A1 (0.35) | — | |
| SCHEMBL15940330 | 0.94 | — | — | |
| SCHEMBL2253133 | 0.94 | — | — | |
| SCHEMBL2253136 | 0.94 | — | — | |
| Methylamine SCHEMBL27938861 | 0.93 | ALDH1A1 (0.32) | — | |
| SCHEMBL1504345 | 0.88 | — | — | |
| SCHEMBL1504344 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564593-B2 | Topical formulation for a JAK inhibitor | INCYTE CORPORATION (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250345337-A1 | TOPICAL FORMULATION FOR A JAK INHIBITOR | INCYTE CORP (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2024184926-A1 | PROCESS FOR PREPARATION OF CHIRAL RUXOLITINIB AND SALTS THEREOF | AARTI PHARMALABS LIMITED (IN) | 2024-09-12 | — | — | WO | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230277541-A1 | TOPICAL FORMULATION FOR A JAK INHIBITOR | INCYTE CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| WO-2023042224-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE | NATCO PHARMA LIMITED (IN) | 2023-03-23 | — | — | WO | disclosed |
| US-11590136-B2 | Topical formulation for a JAK inhibitor | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| US-11571425-B2 | Topical formulation for a JAK inhibitor | INCYTE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| CN-101448826-A | Heteroaryl substituted pyrrolo [2 ] as janus kinase inhibitors | INCYTE CORP (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-1966202-A1 | HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |